
Opinion|Videos|November 27, 2024
Managing Treatment Challenges in HER2-Directed Therapies
Key Takeaways
- Understanding molecular mechanisms of resistance is crucial for developing novel therapeutic agents and combination strategies in HER2-directed therapies.
- Personalized medicine, utilizing genomic profiling, is expected to tailor treatments to individual patient profiles, enhancing efficacy.
An exploration of emerging strategies to overcome resistance to HER2-directed therapies based on ongoing research advancements.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- How might strategies to address resistance to HER2-directed therapies evolve with ongoing research?
Advertisement
Related to this article

The Autus Size-Adjustable Valve, which can be expanded as children grow, may reduce the need for repeat open-heart surgeries for congenital defects.

Phase 3 wins for ianalumab and dazodalibep bring targeted therapies closer for Sjögren disease as patients face diagnostic delays and high costs.

Although PMOS Awareness Month has ended, the conversation continues, with experts saying closing diagnostic and care gaps requires ongoing efforts.

Invivyd's VYD2311 shows superior safety and tolerability vs Comirnaty in the phase 3 LIBERTY trial, with no vaccine interference.

Survodutide achieved up to 13.1% weight loss vs 3.1% with placebo at 76 weeks in adults with obesity and T2D in the phase 3 SYNCHRONIZE-2 trial.

A rare case of soft-tissue sarcoma spreading to the heart shows how multimodal imaging guided diagnosis and care in a 36-year-old man.
Advertisement
Advertisement
Trending on AJMC
1
Perspectives on Health-Related Social Needs for Medicare Advantage Beneficiaries
2
Systemic Sclerosis Linked to Dramatic Rise in Lung Cancer Risk
3
FDA Approves First Heart Valve to Keep Pace With Children's Growth
4
Psoriasis Is Much Rarer in Indigenous Groups Worldwide
5


